申请人:King Abdulaziz University
公开号:US10836736B1
公开(公告)日:2020-11-17
A compound of formula (I),
wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, and R3 is an optionally substituted alkylamino, an optionally substituted cycloalkylamino, an optionally substituted arylamino, an optionally substituted heterocyclylamino, an optionally substituted heterocyclyl, and an optionally substituted dialkylamino. A pharmaceutical composition which includes the compound of formula (I) and a pharmaceutically acceptable carrier and/or excipient. A method of treating colorectal cancer in a subject, whereby a therapeutically effective amount of the compound of formula (I) is administered to the subject.
化合物的化学式为(I),其中R1是可选取代的芳基或可选取代的杂环基,R2是可选取代的芳基或可选取代的杂环基,R3是可选取代的烷基氨基,可选取代的环烷基氨基,可选取代的芳基氨基,可选取代的杂环基氨基,可选取代的杂环基和可选取代的二烷基氨基。一种制备方法包括化合物(I)和药学上可接受的载体和/或赋形剂的制药组合物。一种治疗结直肠癌的方法,通过向患者施用化合物(I)的治疗有效量。